Related Experiment Video
Updated: May 15, 2025
07:34
Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research
Published on: December 15, 2023
1.7K
Effects of stem cell therapy on preclinical stroke
Gita Serafika Shannon1, Ratih Rinendyaputri2, Sunarno Sunarno2
1Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
Open Veterinary Journal
|April 9, 2025
Summary
Mesenchymal stem cell (MSC) secretomes show promise for stroke recovery by reducing inflammation and promoting brain repair. These cell-free therapies offer neuroprotection and enhance neural function after ischemic stroke.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Biomedical Engineering
Background:
- Ischemic stroke is a major cause of death and disability worldwide, resulting from obstructed blood flow to the brain.
- Current treatments like tPA and MT have limitations in neural repair and carry risks.
- Stem cell therapies, particularly mesenchymal stem cells (MSCs), offer neuroprotection and enhance recovery.
Purpose of the Study:
- To review the potential of MSC-derived secretomes, including extracellular vesicles (EVs) and exosomes, for treating ischemic stroke.
- To explore the neuroprotective and regenerative mechanisms of MSC secretomes.
- To discuss translational challenges and future directions for integrating MSC secretomes with conventional stroke therapies.
Main Methods:
- Synthesis of current preclinical in vitro and in vivo studies on MSC secretomes in ischemic stroke models.
- Analysis of the composition and function of MSC secretomes, focusing on bioactive molecules like microRNAs, proteins, and cytokines.
- Review of evidence supporting MSC secretomes in reducing neuroinflammation, promoting angiogenesis, neurogenesis, and neuronal survival.
Main Results:
- MSC secretomes, rich in neuroprotective factors, effectively reduce neuroinflammation and oxidative stress in preclinical models.
- These cell-free components promote angiogenesis, neurogenesis, and neuronal survival, contributing to functional recovery after ischemic stroke.
- MSC secretomes demonstrate efficacy in preserving neurovascular integrity and modulating immune responses in ischemic environments.
Conclusions:
- MSC-derived secretomes represent a promising cell-free therapeutic strategy for ischemic stroke, offering multifaceted neuroprotective and regenerative benefits.
- Further research and clinical translation are needed to overcome challenges in optimizing delivery and efficacy.
- Integrating MSC secretome therapy with conventional treatments holds significant potential for improving outcomes in ischemic stroke patients.
